CD209 and neoplasm: In a B16-OVA mouse model, we demonstrated that our liposomal vaccine platform composed of the iNKT activator αGC, DC-SIGN-targeting glycan LeY, and T-cell epitope containing SLP, in combination with αPD1 and αCD40, is able to decrease tumor outgrowth.